Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RNV-3001
- Development stage
- Preclinical
- Lead developer
- REDNVIA
- Modality
- Small Molecules
01
Overview
RNV-3001 is a discovery-stage pharmaceutical candidate being developed by REDNVIA, a South Korean biotechnology company specializing in cardiovascular diseases. REDNVIA was established as a spin-off from the Asan Medical Center to focus on the development of treatments for calcific aortic valve disease (CAVD) and other cardiovascular calcification disorders. RNV-3001 is currently positioned in the discovery phase for general cardiovascular indications. While the company's lead programs utilize small molecule inhibitors to target calcification pathways, the specific molecular target and modality for RNV-3001 have not been publicly disclosed as of early 2024.
Beyond the preview
Go deeper on RNV-3001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNV-3001.